Literature DB >> 24474253

VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis.

Qing Guo1, Sheng-Bin Dai, Feng Shen, Di Yu, Shu-Tong Shen, Qu Zhang, Jun-Xing Huang, Zheng-Dong Wu.   

Abstract

Vascular endothelial growth factor (VEGF) polymorphisms, specifically +405G/C (rs2010963), reportedly influence the risk for various digestive cancers. However, the consequences of these polymorphisms remain controversial and ambiguous. Therefore, we performed a meta-analysis of 11 studies with VEGF +405G/C genotyping on 2,862 patients and 3,028 controls using the random effects model. We obtained a pooled odds ratio (OR) of 1.04 (95% confidence interval (CI) = 0.86-1.26) for the recessive genetic model, 1.07 (95% CI = 0.81-1.42) for the dominant genetic model, 1.09 (95% CI = 0.81-1.47) for the homozygote comparison, and 1.03 (95% CI = 0.83-1.27) for the heterozygote comparison. In the subgroup analysis of the recessive model, the OR was 1.20 (95% CI = 1.02-1.40) in colorectal cancer. These results show that VEGF +405G/C polymorphisms are unlikely to be a major determinant of susceptibility to digestive cancer. Furthermore, the subgroup analysis of recessive model indicates that VEGF +405G/C polymorphisms increase the risk for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24474253     DOI: 10.1007/s13277-014-1655-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

1.  Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.

Authors:  Rihong Zhai; Geoffrey Liu; Kofi Asomaning; Li Su; Matthew H Kulke; Rebecca S Heist; Norman S Nishioka; Thomas J Lynch; John C Wain; Xihong Lin; David C Christiani
Journal:  Carcinogenesis       Date:  2008-09-09       Impact factor: 4.944

Review 2.  Vascular endothelial growth factor as a target for anticancer therapy.

Authors:  Napoleone Ferrara
Journal:  Oncologist       Date:  2004

3.  Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms--a case-control study in an Omani population.

Authors:  Mansour S Al-Moundhri; Maryam Al-Nabhani; Ikram A Burney; Abdul-Aziz Al-Farsi; Bassim Al-Bahrani
Journal:  Mol Carcinog       Date:  2009-12       Impact factor: 4.784

4.  Positive association of the vascular endothelial growth factor-A +405 GG genotype and poor survival in stage I-II gastric cancer in the Northern Chinese population.

Authors:  Ailin Li; Peng Gao; Zhenning Wang; Yongxi Song; Yingying Xu; Yuan Miao; Jinliang Zhu; Huimian Xu
Journal:  Mol Biol Rep       Date:  2012-12-23       Impact factor: 2.316

5.  Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk.

Authors:  Guenter Hofmann; Uwe Langsenlehner; Wilfried Renner; Tanja Langsenlehner; Babak Yazdani-Biuki; Heimo Clar; Armin Gerger; Martin Wehrschuetz; Hellmut Samonigg; Peter Krippl
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-16       Impact factor: 4.553

6.  Positive association between vascular endothelial growth factor (VEGF) -2578 C/A variant and prostate cancer.

Authors:  M L Martinez-Fierro; I Garza-Veloz; A Rojas-Martinez; R Ortiz-Lopez; C Castruita-de la Rosa; Y Ortiz-Castro; B P Lazalde-Ramos; A R Cervantes-Villagrana; M E Castañeda-Lopez; L Gomez-Guerra; I Delgado-Enciso; A A Martinez-Torres
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

7.  Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: a meta-analysis involving 30 studies.

Authors:  Kai Hu; Yong Zhang; Rensheng Wang; Guojian Li; Guihua Li; Dawei Zhang
Journal:  Twin Res Hum Genet       Date:  2012-08       Impact factor: 1.587

8.  Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival.

Authors:  Konstantinos Dassoulas; Maria Gazouli; Spyros Rizos; George Theodoropoulos; Zoi Christoni; Nikolaos Nikiteas; Petros Karakitsos
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

9.  Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer.

Authors:  Guo-Qiang Chen; Jian-bin Luo; Guang-Zhi Wang; Jin-E Ding
Journal:  Tumour Biol       Date:  2013-12-19

10.  Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer.

Authors:  Yee Soo Chae; Jong Gwang Kim; Sang Kyun Sohn; Yoon Young Cho; Byung Min Ahn; Joon Ho Moon; Seoung Woo Jeon; Jae Yong Park; In Taek Lee; Gyu Seog Choi; Soo-Han Jun
Journal:  J Korean Med Sci       Date:  2008-06       Impact factor: 2.153

View more
  5 in total

1.  Prognostic effect of p53 expression in patients with completely resected colorectal cancer.

Authors:  Bin-Wei Liu; Yang Liu; Jun-Ru Liu; Zhong-Xu Feng; Tong Liu
Journal:  Tumour Biol       Date:  2014-07-04

2.  Genetic variants and risk of esophageal squamous cell carcinoma: a GWAS-based pathway analysis.

Authors:  Xi Yang; Hongcheng Zhu; Qin Qin; Yuehua Yang; Yan Yang; Hongyan Cheng; Xinchen Sun
Journal:  Gene       Date:  2014-11-26       Impact factor: 3.688

3.  TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Qing Guo; Jia He; Feng Shen; Wei Zhang; Xi Yang; Chi Zhang; Qu Zhang; Jun-Xing Huang; Zheng-Dong Wu; Xin-Chen Sun; Sheng-Bin Dai
Journal:  Oncol Lett       Date:  2016-12-20       Impact factor: 2.967

4.  Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.

Authors:  Eva Dreussi; Erika Cecchin; Jerry Polesel; Vincenzo Canzonieri; Marco Agostini; Caterina Boso; Claudio Belluco; Angela Buonadonna; Sara Lonardi; Francesca Bergamo; Sara Gagno; Elena De Mattia; Salvatore Pucciarelli; Antonino De Paoli; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2016-09-05       Impact factor: 5.923

5.  A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.

Authors:  Elena De Mattia; Eva Dreussi; Marcella Montico; Sara Gagno; Chiara Zanusso; Luca Quartuccio; Salvatore De Vita; Michela Guardascione; Angela Buonadonna; Mario D'Andrea; Nicoletta Pella; Adolfo Favaretto; Enrico Mini; Stefania Nobili; Loredana Romanato; Erika Cecchin; Giuseppe Toffoli
Journal:  Front Pharmacol       Date:  2018-10-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.